References
- Ames, B. N., Lee, F. D., Durston, W. E. (1973). An improved bacterial test system for the detection and classification of mutagens and carcinogens. PNAS 70:782–786.
- Bratkowska-Seniow, B., Oleszkiewicz, L., Kozak, E., Krizar, T. (1976). Ledakrin in the treatment of colon carcinoma. Mat Med Pol 8:323–330.
- Denny, W. A. (2002). Acridine derivatives as chemotherapeutic agents. Curr Med Chem 9:1655–1665.
- Ferguson, L. R., Denny, W. A. (1990). Frameshift mutagenesis by acridines and other reversibly-binding DNA ligands. Mutagenesis 5:539–551.
- Ferguson, L. R., Denny, W. A. (1991). The genetic toxicology of acridines. Mutat Res 258:23–160.
- Gorlewska, K., Mazerska, Z., Sowinski, P., Konopa, J. (2001). Products of metabolic activation of the antitumor drug ledakrin (Nitracrine) in vitro. Chem Res Toxicol 14:1–10.
- ICH Guideline S2B. (1998). Genotoxicity: a standard battery for genotoxicity testing of pharmaceuticals. London: European Medicines Agency.
- Kaleeswaran, S., Sriram, P., Prabhu, D., Chinnathambi, Vijayakumar, Mathuram L. N. (2009). Anti- and pro-mutagenic effects of silymarin in the Ames bacterial reverse mutation assay. Phytother Res 23:1378–1384.
- Kropko, M. L., Wold, J. C. (1992). Comparative bacterial mutagenicity of tacrine and selected aminoacridine compounds. Environ Mol Mutagen 19:32.
- Madle, S., Korte, A., Ball, R. (1987). Experience with mutagenicity testing of new drugs: viewpoint of a regulatory agency. Mutat Res 182:187–192.
- Mortelmans, K., Zeiger, E. (2000). The Ames Salmonella/microsome mutagenicity assay. Mutat Res 455:29–60.
- OECD Guideline 474. (1997). OECD guideline for the testing of chemicals: 474. Mammalian erythrocyte micronucleus test. London: European Medicines Agency.
- Schmid, W. (1975). The micronucleus test. Mutat Res 31:9–15.
- Shaddock, J. G., Feures, R. J., Chou, M. W., Swenson, D. H., Casciano, D. A. (1995). Genotoxicity of tacrine in primary hepatocytes isolated from B6C3F1 mice and aged ad libitum and calorie restricted Fischer 344 rats. Mutat Res 344:79–88.
- Snyder, R. D., McNulty, J., Zairov, G., Ewing, D. E., Hendry, L. B. (2005). The influence of N-dialkyl and other cationic substituents on DNA intercalation and genotoxicity. Mutat Res 578:88–99.
- Sram, R. J., Kocisova, K., Kodytkova, I. (1984). Chromosomal aberration in mouse bone marrow induced by tacrine. Activ Nerv Suppl (Praha) 23:84–86.
- Studzian, K., Tolwinska-Stanczyk, Z., Wilmanska, D., Palumbo, M., Gniazdowski, M. (1999). Crosslinking of cellular DNA by nitracrine and furocoumarin derivatives. Neoplasma 46:50–53.
- Sweetman, S. (2004). Martindale: the complete drug reference (34th ed). London: Pharmaceutical Press.
- Tennant, R. W., Margolin, B. H., Shelby, M. D., Zeiger, E., Haseman, J. K., Spalding, J., et al. (1987). Prediction of chemical carcinogenicity in rodents from in vitro genetic toxicity assays. Science 236:933–941.
- Townsend, S. E., Sehgal, S. N. (1988). Mutagenicity evaluation of tetrahydro amino acridine (THA) by the Salmonella/microsome mutagenicity test (Ames test). Environ Mol Mutagen 11:106.
- Wassom, J. (1992). Origins of genetic toxicology and the environmental Mutagen Society. Environ Mol Mutagen 14:1–6.
- Zeiger, E., Erexson, G., Mortelmans, K., Thilagar, A. (1997). Genetic toxicity studies of 1,2,3,4-tetrahydro-9-acridinamine (tacrine). Mutat. Res 393:189–197.